269 related articles for article (PubMed ID: 10745943)
1. [Bone hyperresorption in multiple myeloma].
Beaudreuil J; Orcel P
Presse Med; 2000 Mar; 29(9):492-7. PubMed ID: 10745943
[TBL] [Abstract][Full Text] [Related]
2. [Bisphosphonates in the treatment of multiple myeloma].
Stajszczyk M
Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates in the treatment of malignant bone disease.
Berenson JR; Lipton A
Annu Rev Med; 1999; 50():237-48. PubMed ID: 10073275
[TBL] [Abstract][Full Text] [Related]
4. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma.
Bataille R; Chappard D; Klein B
Int J Clin Lab Res; 1992; 21(4):283-7. PubMed ID: 1591381
[TBL] [Abstract][Full Text] [Related]
5. [Role of diphosphonates in the therapy of osteolysis and malignant hypercalcemia].
Delmas PD; Charhon SA; Chapuy MC; Meunier PJ
Rev Rhum Mal Osteoartic; 1984 Dec; 51(11):663-6. PubMed ID: 6523018
[No Abstract] [Full Text] [Related]
6. Use of bisphosphonates in cancer patients.
Body JJ; Coleman RE; Piccart M
Cancer Treat Rev; 1996 Jul; 22(4):265-87. PubMed ID: 9025784
[No Abstract] [Full Text] [Related]
7. Mechanisms of bone lesions in multiple myeloma and lymphoma.
Roodman GD
Cancer; 1997 Oct; 80(8 Suppl):1557-63. PubMed ID: 9362422
[TBL] [Abstract][Full Text] [Related]
8. [Bone targeting agents: bisphosphonates].
Debiais F
Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
[TBL] [Abstract][Full Text] [Related]
9. [Bone hyperresorption in neoplastic diseases. Foreword].
Vinceneux P
Presse Med; 2000 Mar; 29(9):485-6. PubMed ID: 10745941
[No Abstract] [Full Text] [Related]
10. Bisphosphonates in multiple myeloma.
Apperley JF; Croucher PI
Pathol Biol (Paris); 1999 Feb; 47(2):178-81. PubMed ID: 10192885
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis.
Clézardin P; Gligorov J; Delmas P
Joint Bone Spine; 2000 Jan; 67(1):22-9. PubMed ID: 10773965
[TBL] [Abstract][Full Text] [Related]
13. The use of clodronate in multiple myeloma.
Delmas PD
Bone; 1991; 12 Suppl 1():S31-4. PubMed ID: 1835398
[TBL] [Abstract][Full Text] [Related]
14. The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.
Harvey HA; Lipton A
Support Care Cancer; 1996 May; 4(3):213-7. PubMed ID: 8739655
[TBL] [Abstract][Full Text] [Related]
15. New diphosphonates to block bone resorption.
Raisz LG
N Engl J Med; 1980 Feb; 302(6):347-8. PubMed ID: 6444242
[No Abstract] [Full Text] [Related]
16. Advances in the biology and treatment of myeloma bone disease.
Berenson JR
Semin Oncol; 2002 Dec; 29(6 Suppl 17):11-6. PubMed ID: 12520479
[TBL] [Abstract][Full Text] [Related]
17. [Hypercalcemia in myeloma].
Abe M
Nihon Rinsho; 2007 Dec; 65(12):2245-9. PubMed ID: 18069268
[TBL] [Abstract][Full Text] [Related]
18. Use of bisphosphonates in patients with metastatic bone disease.
Berenson JR; Lipton A
Oncology (Williston Park); 1998 Nov; 12(11):1573-9; discussion 1579-81. PubMed ID: 9834935
[TBL] [Abstract][Full Text] [Related]
19. [Action of bisphosphonates on malignant osteolysis].
Alexandre C
Presse Med; 1999 Sep; 28(28):1536-40. PubMed ID: 10526564
[TBL] [Abstract][Full Text] [Related]
20. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
